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Cancer is one of the leading causes of death globally. Although more than 400 varieties of cancer have been 
reported, based on cell lines, still the actual reason of all types of cancer is not very clear. Several internal and 
external factors have been identified and the study is ongoing. Up to now about 73 proteins have been identified 
that are capable to influence directly various phases of cancer including mutation, cell proliferation, invasion, 
angiogenesis, and metastasis. Cytidine deaminase is one of the important proteins that is responsible for various 
types of cancer that includes gastric, liver, biliary tract, bladder, breast, pancreatic ductal adenocarcinoma 
(PDAC) and so on. Two excellent inhibitors of cytidine deaminase are commercially available. A brief overview 
is presented in this advanced review. Any omission is completely unintentional. 
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Introduction 
Cancer is the second leading cause of death worldwide 
and about 8.8 million people died in cancer only in 2015. 
Late-stage determination and limited accessibility in 
diagnosis/pathological evaluations, and subsequent 
treatment, particularly in the low- and middle-income 
countries, are very frequent. It is imperative to mention that 
about 1 in 6 deaths around the world is due to cancer [1]. On 
the other hand, appropriate knowledge and understanding of 
molecular targets are an important part in the battle against 
cancer. In fact a huge number of proteins play crucial role in 
different stages of cancer starting from DNA mutation, 
invasion, angiogenesis, metastasis and so on [2]. Deaminases 
are enzymes that catalyze deamination of a molecule, a 
process that removes an amine group from the molecule by 
means of hydrolysis. This occurs in the liver or kidneys and 
usually the enzyme will remove only one amine group from 
any extra proteins. Cytidine deaminases (CDA) are the 
members of multisubunit enzymes (allosteric enzymes) 
family that are found in every mammal. It is encased in 
human tissues, organs, and it is encoded in the CDA gene. 
The CDA gene encodes this enzyme that is involved in 
pyrimidine salvaging. The protein that is then encoded, forms 
a homotetramer that causes a catalyzation that in itself is an 
irreversible hydrolytic deamination of cytidine and 
deoxycytidine to uridine and lastly deoxyuridine. There are 
several deaminases that are responsible to maintain of the 
cellular pyrimidine pool, this particular one is one of them [3].  
REVIEW 
Cancer Cell & Microenvironment 2017; 4: e1584. doi: 10.14800/ccm.1584; © 2017 by Claudia A. Almaraz, et al. 
http://www.smartscitech.com/index.php/ccm 
 
Page 2 of 3 
 
Discussion 
It is well-known that cancer starts primarily by developing 
certain mutations in DNA. DNA contains certain genes that 
activate and signal the corresponding cell what to do and 
how to do it. The only issue here is when those instructions 
inadvertently create errors that hinder the natural cellular 
processes. Cell mutations may happen in multiple ways; it 
can be by birth and develop sometimes thereafter or it be 
caused due to external factors. There are over 400 types of 
cancers that exist and with that multiple types of pathways  
attempt to defeat them before they metastasize, with the most 
common CDA-dependent types include, but are not limited 
to, bladder, breast, colon, lung, melanoma, prostate, thyroid 
kidney, endometrial, pancreatic and non-Hodgkin’s 
lymphoma. Studies have linked cytidine deaminase to 
activation of mutation that creates certain cancers. APBOEC 
(catalytic polypeptide-like), a family of evolutionarily 
conserved CDAs, are involved in several significant 
biochemical processes in human body such as antibody 
diversification/maturation, restriction of viral infection, and 
generation of somatic mutations. APBOEC is wide spread in 
various human cancers which mentions the correlation to 14 
different types of cancer found through a genome and exome 
data set criteria. APOBEC3 protein families, a DNA cytidine 
deaminase, are up-regulated in several types of cancer. The 
application to these criteria was applied to 954,247 mutations 
in 2,680 exomes. The APOBEC pattern of mutation was 
present in bladder, cervical, breast, lung, and head and neck 
cancer. It was found to reach 68% of the mutation patterns in 
some samples. Multiple studies have concluded the similar 
findings with correlation between CDA and cancer. CDA in 
this instance was concluded to be a necessary expression for 
the development of cancer in animal models as well as those 
found in human skin cancers such as melanoma, and head 
and neck cancer. It has been reported that mutation 
demonstrated by an oncogene or tumor suppressor gene 
expression that when heavily accumulated the mutation this 
would result in cancer. The cytidine deaminase family, is an 
essential enzyme for somatic hyper mutation and additionally 
for class-switch recombination of antibody genes. It was also 
reported that there is involvement of cytidine deaminases the 
development of cancers in the gastrointestinal tract, 
mammary gland, and prostate[4-10]. Interestingly, 
downregulation of cytidine deaminase was reported for the 
patients with Bloom syndrome, a genetic disease related to a 
strong predisposition to a wide range of cancers. Recently it 
has been reported that CDA-deficient tumor cells can be 
specifically targeted with small molecule antitumor drugs, 
opening up new possibilities to treat cancer[11]. APOBEC3 
and AID boost immune response by mutating immune or 
viral genes. Because of their genome-mutating activities 
these proteins are capable to promote tumorigenesis. AID is a 
198 amino acid DNA-editing enzyme that deaminates dC to 
dU in ssDNA. AID promotes hypermutation in 
immunoglobulin (Ig) loci that induces genome-wide 
mutations, subsequent breaking of double-strand leads tumor 
formation [12-18].  
Human CDA plays major role to catalyze metabolic 
processing of nucleoside-type anticancer and antiviral agents. 
Accordingly, it is a promising target for the development of 
small molecule anticancer adjuvants. Two well-known 
commercially available cytidine deaminase inhibitors are 
shown in Figure 1. Zebularine binds to the active site as 
covalent hydrates and inhibits in vitro DNA-methylation and 
subsequently tumor growth is inhibited in vivo. On the other 
hand, the orally active drug THU modulates antiproliferative 
effects. 
Conclusion 
Cytidine deaminases are prevalent in many organisms and 
in human CDA plays major role to develop certain types of 
cancer. Although several studies have had been conducted 
around the globe still more precise investigation is obligatory 
to reveal a better picture. Development of more effective 
inhibitors with higher potency (to the malignant cells) and 
lower toxicity (to the normal cells) are timely and 
challenging to encounter cancer. 
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Figure 1. Commercially available CDA inhibitors Zebularine and 
Tetrahydrouridine (THU). 
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